Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

5.700 +0.060 (+1.06%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder. 
Via The Motley Fool
Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying
Via Benzinga
Analyst Ratings For Amylyx Pharma
Via Benzinga
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and... 
Via Benzinga
6 Analysts Assess Amylyx Pharma: What You Need To Know
Via Benzinga
Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
Via Benzinga
Unveiling 6 Analyst Insights On Amylyx Pharma
Via Benzinga
Amylyx Stock Crashes 80% After Approved ALS Drug Fails Its Pivotal Test
The company could now pull Relyvrio off the market. 
Via Investor's Business Daily
AMLX Stock Earnings: Amylyx Pharma Misses EPS, Misses Revenue for Q1 2024
AMLX stock results show that Amylyx Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder
Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, visual decline, and overall disease burden. Safety profile consistent. 
Via Benzinga
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
Seelos Therapeutics updates Phase 2/3 HEALEY ALS trial with SLS-005, showing potential efficacy in subgroup analysis. Explore the latest data on ALS treatment with SLS-005." 
Via Benzinga
3 Pharma Stocks to Sell in March Before They Crash & Burn
Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions. 
Via InvestorPlace
Dow Gains Over 100 Points; AerSale Shares Plunge After Q4 Results
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dipping around 0.5% on Friday. The Dow traded up 0.27% to 38,894.21 while the NASDAQ fell 0.51% to 16,190.52. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Forecasting The Future: 4 Analyst Projections For Amylyx Pharma
Via Benzinga
Earnings Preview: Amylyx Pharma
Via Benzinga
Stocks Fall As Chipmakers Retreat From Highs, Bitcoin Pulls Back After $70,000, Gold Rises To $2,200: What's Driving Markets Friday?
The stock market is navigating a mixed closing session this week, with the S&P 500 and Nasdaq 100 struggling to stave off a weekly downturn. 
Via Benzinga
Crude Oil Falls Over 1%; Willdan Group Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 80 points on Friday. The Dow traded up 0.21% to 38,874.05 while the NASDAQ fell 0.42% to 16,204.26. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Is Neurodegenerative Diseases-Focused Amylyx Pharmaceuticals Stock Plunging On Friday?
Amylyx Pharmaceuticals' AMX0035 trial results for ALS. Amylyx plans regulatory discussions and potential market actions. AMX0035's ongoing studies in PSP and Wolfram syndrome. 
Via Benzinga
Nasdaq Gains Over 50 Points; US Economy Adds 275,000 Jobs In February
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Friday. Following the market opening Friday, the Dow traded up 0.04% to 38,805.52 while the NASDAQ rose 0.41%... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
The Top 3 Biotech Stocks to Buy in March 2024
Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors. 
Via InvestorPlace
7 Oversold Russell 2000 Stocks to Add to Your February Buy List
Investors may want to jump into oversold Russell 2000 stocks. After a rough outing in 2023, many are starting to come back strong. 
Via InvestorPlace
Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Etsy, Inc. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NICE Posts Upbeat Earnings, Joins FTI Consulting, NVIDIA, Moderna And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Amylyx Stock Rockets As ALS Drug Tacks On Another Triple-Digit Quarter
The company launched its first drug in late 2022. Sales grew rapidly, but look to slow down this year. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.